Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer

The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) and has demonstrated efficacy in later lines. Progressive disease (PD) occurs wh...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:ESMO Open
Main Authors: Goldberg, Richard M, Montagut, Clara, Wainberg, Zev A, Ronga, Philippe, Audhuy, François, Taieb, Julien, Stintzing, Sebastian, Siena, Salvatore, Santini, Daniele
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2018
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950648/
https://ncbi.nlm.nih.gov/pubmed/29765773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000353
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki